Relation between bevacizumab dose intensity and high-grade glioma survival: A retrospective study in two large cohorts

Journal of Neuro-Oncology

Volumn 107, Issue 2, 2012, Pages 351-358

  Lorgis, Veronique ^a   Maura, Geric ^a   Coppa, Guillaume ^b   Hassani, Kahina ^b   Taillandier, Luc ^b   Chauffert, Bruno ^c   Apetoh, Lionel ^d,e   Ladoire, Sylvain ^a,d,e   Ghiringhelli, François ^a,d,e  

^a Georges Francois Leclerc Cancer Center   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c AMIENS UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ DE BOURGOGNE   (France)

^e boulevard Jeanne d'Arc   (France)

Author keywords

Bevacizumab; Glioblastoma; Prognostic factor

Indexed keywords

BEVACIZUMAB; IRINOTECAN; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BRAIN HEMORRHAGE; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; FATIGUE; FEMALE; FOLLOW UP; GLIOBLASTOMA; GLIOMA; HUMAN; HYPERTENSION; INFECTION; KARNOFSKY PERFORMANCE STATUS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROSURGERY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; SURVIVAL TIME; THROMBOCYTOPENIA; VALIDATION STUDY; VOMITING; BRAIN TUMOR; DISEASE FREE SURVIVAL; DOSE RESPONSE; MIDDLE AGED; MORTALITY; REPRODUCIBILITY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; COHORT STUDIES; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862555221     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0748-5     Document Type: Article

References (29)

1. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996
2. Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572-2578
3. Lamborn KR, Yung WK, Chang SM et al (2008) Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 10:162-170
4. Ballman KV, Buckner JC, Brown PD et al (2007) The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol 9:29-38
5. Yung WK, Albright RE, Olson J et al (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588-593
6. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8:610-622
7. Gupta K, Radotra BD, Banerjee AK, Nijhawan R (2004) Quantitation of angiogenesis and its correlation with vascular endothelial growth factor expression in astrocytic tumors. Anal Quant Cytol Histol 26:223-229
8. Hong YK, Lange-Asschenfeldt B, Velasco P et al (2004) VEGFA promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha1beta1 and alpha2beta1 integrins. Faseb J 18:1111-1113
9. Nam DH, Park K, Suh YL, Kim JH (2004) Expression of VEGF and brain specific angiogenesis inhibitor-1 in glioblastoma: prognostic significance. Oncol Rep 11:863-869
10. Takano S, Tsuboi K, Matsumura A, Nose T (2003) Anti-vascular endothelial growth factor antibody and nimustine as combined therapy: effects on tumour growth and angiogenesis in human glioblastoma xenografts. Neuro Oncol 5:1-7
11. Sathornsumetee S, Cao Y, Marcello JE et al (2008) Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 26:271-278
12. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342
13. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550
14. Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676
15. Escudier B, Bellmunt J, Negrier S et al (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28:2144-2150
16. Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733-4740
17. Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28: 1963-1972
18. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A (1994) Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367:576-579
19. Folkman J (1985) Tumor angiogenesis. Adv Cancer Res 43:175-203
20. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27-31
21. Parangi S, O'Reilly M, Christofori G et al (1996) Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci USA 93:2002-2007
22. Vredenburgh JJ, Desjardins A, Herndon JE II et al (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253-1259
23. Norden AD, Drappatz J, Muzikansky A et al (2009) An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol 92:149-155
24. Xu T, Chen J, Lu Y, Wolff JE (2010) Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis. BMC Cancer 10:252
25. de Groot JF, Fuller G, Kumar AJ et al (2010) Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 12:233-242
26. Keunen O, Johansson M, Oudin A et al (2011) Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA
27. Lucio-Eterovic AK, Piao Y, de Groot JF (2009) Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res 15:4589-4599
28. de Groot JF (2011) High-dose antiangiogenic therapy for glioblastoma: less may be more? Clin Cancer Res
29. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65